L ife expectancy (LE) and tumor characteristics are clinical factors that affect the likelihood of benefit from curative therapy (CTx) for prostate cancer. Treatment of patients with a shorter LE may contribute to additional costs or complications, without a commensurate improvement in quality of life or survival. [1] [2] [3] The National Comprehensive Cancer Network practice guidelines in oncology 4 recommend active surveillance as an alternative to CTx (radical prostatectomy or radiation therapy) for patients with low-risk tumor characteristics who have an LE of less than 10 years. For patients with intermediate-risk cancers and an LE of 10 years or more, CTx is recommended. 4 Although therapeutic options for patients with prostate cancer have expanded considerably in recent years, little is known about whether the treatment of men with early-stage prostate cancer has evolved. [5] [6] [7] It is unclear whether patterns of care correspond to the likelihood of clinical benefit from treatment, as determined by LE and tumor characteristics. We therefore assessed trends in the use of CTx across strata of potential clinical benefit.
Methods. Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database, we identified men aged 67 to 84 years with localized prostate cancer that was diagnosed between 1998 and 2007, including only patients from registries that existed before the 2000 SEER expansion. We defined low-risk tumors as those with SEER grade 1 or 2 and stage T1 or T2a and moderate-risk tumors as those with SEER grade 3 or 4 or stage T2b-T2c.
A standard life table approach was used to estimate LE as a function of noncancer comorbidity. 8 Specifically, we used a sample of patients without a cancer diagnosis recorded in SEER from the Medicare 5% random sample to determine annual mortality rates for each age and comorbidity stratum and then used these rates to estimate LE. Patients with an LE of less than 5 years, 5 to 10 years, or 10 years or more were classified as having a short, intermediate, or long LE. The 10-year survival rates in these groups were 19.3%, 51.6%, and 76.1%, respectively.
We defined CTx as receipt of radiation therapy or prostatectomy within 9 months of cancer diagnosis, as defined by International Classification of Diseases, Ninth Revision, procedure codes and Healthcare Common Procedure Coding System codes (eAppendix [http: //www.archinternmed.com]). Multivariable logistic regression was used to model the receipt of CTx after controlling for age, race, marital status, comorbidity, and SEER registry. 2 Tests were used to ascertain bivariate associations between the independent variables and the receipt of CTx. Interactions between LE and diagnosis year were assessed in low-and moderate-risk tumor groups. Figure] ). Conversely, the use of CTx decreased from 80.7% to 80.0% among men with a long LE (LEϫTime Interaction, P=.02). Among men with lowrisk tumors, the use of CTx trended downward for men in the long LE category but increased for men in the short and intermediate LE categories (LEϫTime Interaction, PϽ .001).
Results

Comment.
Men with localized prostate cancer may not receive CTx in accordance with clinical benefit. During our study period, there was increasingly aggressive treatment of patients with a low likelihood of clinical benefit, without a commensurate increase in the treatment of patients with a high likelihood of clinical benefit. While not treating potentially fatal cancer can reflect poorquality care, aggressive management of disease that is unlikely to progress puts patients at risk for morbidity and increases cost without medical benefits. 1-3 Given widespread concerns about the rate of increase in Medicare expenditures, it is notable that the most substantial increase in treatment in our sample was noted among the patients who were least likely to benefit. Possible explanations include financial incentives, emergence of new therapies with perceived lower adverse effect profiles, and changes in patient preferences. The use of cancer therapies should be informed by clinical evidence and guided by patient preferences. Future work should explore how better to incorporate both cancer characteristics and patient LE into decision making. 
Increasing US Rates of Endocarditis With Staphylococcus aureus: 1999-2008
E stimates of the incidence and impact of bacterial infective endocarditis (IE) have been limited by the infrequency of the disease. Administrative data analyses can provide important information across a broad range of hospitals and regions. We used a recent nationally representative sample 1 to estimate the incidence of hospitalizations for bacterial IE in the United States.
Methods.
We conducted a retrospective cohort study using the 1999 through 2008 Nationwide Inpatient Sample (NIS), which is produced by the Agency for Healthcare 
